BioCentury | Feb 5, 2020
Product Development

WHO prioritizing Gilead’s remdesivir, designing master protocol for 2019-nCoV outbreak

Gilead’s remdesivir is the most promising candidate for treating 2019-nCoV acute respiratory disease, according to a draft report of WHO’s R&D Blueprint Clinical Trials expert group. The group agreed in principle to design a randomized,...
BioCentury | Feb 5, 2020
Product Development

冠状病毒爆发:来自编辑的信

Publisher's note: the English language version of this article may be found here .  冠状病毒2019-nCoV的爆发使我们所有人停滞前行,盘点我们正在做和应该做的事情,并重新评估我们制定的今年计划。 随着全球卫生当局加大力度以遏制病毒的传播,药物开发人员必须迅速调整,设计诊断剂,开发预防性疫苗和疗法...
BioCentury | Feb 4, 2020
Product Development

The Coronavirus outbreak: Letter from the Editor

The outbreak of the Coronavirus 2019-nCoV has caused us all to stop in our tracks, take stock of what we’re doing and what we should be doing, and reassess the plans we set out for...
BC Extra | Jan 30, 2020
Company News

China guidelines point to HIV protease inhibitors as potential coronavirus treatment

Ascletis is seeking the approval of China’s NMPA for emergency use of its protease inhibitors to treat 2019-nCoV coronavirus after the government released guidelines suggesting AbbVie’s Kaletra as a treatment for the virus. In a...
BC Innovations | Sep 10, 2018
Distillery Therapeutics

Pulmonary

INDICATION: Acute lung injury Mouse studies suggest inhibiting ZMPSTE24 with Kaletra lopinavir/ritonavir could help treat acute lung injury (ALI). In a mouse model of ventilator-induced ALI, systemic ZMPSTE24 knockout decreased markers of injury and increased...
BC Innovations | Aug 23, 2018
Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS Primate studies suggest combining CD4 mimetics with HIV gp120-based vaccines could help prevent HIV. In macaques challenged with simian human immunodeficiency virus (SHIV) immunized with HIV gp120 variants, a CD4 mimetic prevented infection...
BC Week In Review | Aug 3, 2018
Clinical News

Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection

Merck & Co. Inc. (NYSE:MRK) said once-daily oral doravirine (MK-1439) in combination with other antiretroviral therapies (ARTs) led to viral suppression at week 96 in 73.1% of patients vs. 66% of patients treated with ritonavir-boosted...
BC Innovations | Jun 13, 2018
Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS In vitro and cell culture studies identified an allophenylnorstatine-tetrahydrofuranylglycine conjugate-based inhibitor of HIV protease that could help treat protease inhibitor-resistant HIV infection. Chemical synthesis and in vitro activity assays of allophenylnorstatine-tetrahydrofuranylglycine conjugate analogs...
BioCentury | Feb 17, 2018
Politics, Policy & Law

FDA’s bigger piggy bank

FDA plans to use a proposed record-setting funding boost to invest in projects it believes could lead to fundamental improvements in the way medical products are tested, reviewed and manufactured. The goal is to use...
BC Innovations | Nov 15, 2017
Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Cell culture studies identified a Prezista darunavir-based HIV protease inhibitor that could help treat protease inhibitor-resistant HIV/AIDS. Chemical synthesis and testing in human T cell-based viral replication assays of Prezista analogs...
Items per page:
1 - 10 of 470